Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global market for Immuno-Oncology was estimated to be worth US$ 43650 million in 2023 and is forecast to a readjusted size of US$ 116680 million by 2030 with a CAGR of 14.9% during the forecast period 2024-2030
The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Immuno-Oncology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immuno-Oncology by region & country, by Type, and by Application.
The Immuno-Oncology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-Oncology.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type:
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immuno-Oncology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Immuno-Oncology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Immuno-Oncology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Immuno-Oncology Product Introduction
1.2 Global Immuno-Oncology Market Size Forecast
1.3 Immuno-Oncology Market Trends & Drivers
1.3.1 Immuno-Oncology Industry Trends
1.3.2 Immuno-Oncology Market Drivers & Opportunity
1.3.3 Immuno-Oncology Market Challenges
1.3.4 Immuno-Oncology Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Immuno-Oncology Players Revenue Ranking (2023)
2.2 Global Immuno-Oncology Revenue by Company (2019-2024)
2.3 Key Companies Immuno-Oncology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Immuno-Oncology Product Offered
2.5 Key Companies Time to Begin Mass Production of Immuno-Oncology
2.6 Immuno-Oncology Market Competitive Analysis
2.6.1 Immuno-Oncology Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Immuno-Oncology Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Checkpoint Inhibitors
3.1.2 Cytokine-Based Immunotherapy
3.1.3 Cancer Vaccines
3.1.4 CAR-T Cell Therapy
3.1.5 Others
3.2 Global Immuno-Oncology Sales Value by Type
3.2.1 Global Immuno-Oncology Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Immuno-Oncology Sales Value, by Type (2019-2030)
3.2.3 Global Immuno-Oncology Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Drugstores
4.1.3 Others
4.2 Global Immuno-Oncology Sales Value by Application
4.2.1 Global Immuno-Oncology Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Immuno-Oncology Sales Value, by Application (2019-2030)
4.2.3 Global Immuno-Oncology Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Immuno-Oncology Sales Value by Region
5.1.1 Global Immuno-Oncology Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Immuno-Oncology Sales Value by Region (2019-2024)
5.1.3 Global Immuno-Oncology Sales Value by Region (2025-2030)
5.1.4 Global Immuno-Oncology Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Immuno-Oncology Sales Value, 2019-2030
5.2.2 North America Immuno-Oncology Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Immuno-Oncology Sales Value, 2019-2030
5.3.2 Europe Immuno-Oncology Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Immuno-Oncology Sales Value, 2019-2030
5.4.2 Asia Pacific Immuno-Oncology Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Immuno-Oncology Sales Value, 2019-2030
5.5.2 South America Immuno-Oncology Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Immuno-Oncology Sales Value, 2019-2030
5.6.2 Middle East & Africa Immuno-Oncology Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Immuno-Oncology Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Immuno-Oncology Sales Value
6.3 United States
6.3.1 United States Immuno-Oncology Sales Value, 2019-2030
6.3.2 United States Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Immuno-Oncology Sales Value, 2019-2030
6.4.2 Europe Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Immuno-Oncology Sales Value, 2019-2030
6.5.2 China Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.5.3 China Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Immuno-Oncology Sales Value, 2019-2030
6.6.2 Japan Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Immuno-Oncology Sales Value, 2019-2030
6.7.2 South Korea Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Immuno-Oncology Sales Value, 2019-2030
6.8.2 Southeast Asia Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Immuno-Oncology Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Immuno-Oncology Sales Value, 2019-2030
6.9.2 India Immuno-Oncology Sales Value by Type (%), 2023 VS 2030
6.9.3 India Immuno-Oncology Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Profile
7.1.2 Bristol-Myers Squibb Main Business
7.1.3 Bristol-Myers Squibb Immuno-Oncology Products, Services and Solutions
7.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.1.5 Bristol-Myers Squibb Recent Developments
7.2 Merck & Co., Inc.
7.2.1 Merck & Co., Inc. Profile
7.2.2 Merck & Co., Inc. Main Business
7.2.3 Merck & Co., Inc. Immuno-Oncology Products, Services and Solutions
7.2.4 Merck & Co., Inc. Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.2.5 Merck & Co., Inc. Recent Developments
7.3 Roche AG
7.3.1 Roche AG Profile
7.3.2 Roche AG Main Business
7.3.3 Roche AG Immuno-Oncology Products, Services and Solutions
7.3.4 Roche AG Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.3.5 AstraZeneca, Plc Recent Developments
7.4 AstraZeneca, Plc
7.4.1 AstraZeneca, Plc Profile
7.4.2 AstraZeneca, Plc Main Business
7.4.3 AstraZeneca, Plc Immuno-Oncology Products, Services and Solutions
7.4.4 AstraZeneca, Plc Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.4.5 AstraZeneca, Plc Recent Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Profile
7.5.2 Sanofi S.A. Main Business
7.5.3 Sanofi S.A. Immuno-Oncology Products, Services and Solutions
7.5.4 Sanofi S.A. Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi S.A. Recent Developments
7.6 Dendreon Pharmaceuticals
7.6.1 Dendreon Pharmaceuticals Profile
7.6.2 Dendreon Pharmaceuticals Main Business
7.6.3 Dendreon Pharmaceuticals Immuno-Oncology Products, Services and Solutions
7.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.6.5 Dendreon Pharmaceuticals Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis Immuno-Oncology Products, Services and Solutions
7.7.4 Novartis Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.7.5 Novartis Recent Developments
7.8 Gilead Sciences Inc.
7.8.1 Gilead Sciences Inc. Profile
7.8.2 Gilead Sciences Inc. Main Business
7.8.3 Gilead Sciences Inc. Immuno-Oncology Products, Services and Solutions
7.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.8.5 Gilead Sciences Inc. Recent Developments
7.9 Merck KGaA
7.9.1 Merck KGaA Profile
7.9.2 Merck KGaA Main Business
7.9.3 Merck KGaA Immuno-Oncology Products, Services and Solutions
7.9.4 Merck KGaA Immuno-Oncology Revenue (US$ Million) & (2019-2024)
7.9.5 Merck KGaA Recent Developments
8 Industry Chain Analysis
8.1 Immuno-Oncology Industrial Chain
8.2 Immuno-Oncology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Immuno-Oncology Sales Model
8.5.2 Sales Channel
8.5.3 Immuno-Oncology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
*If Applicable.